Form 8-K - Current report:
SEC Accession No. 0001641172-25-017285
Filing Date
2025-07-01
Accepted
2025-07-01 08:55:07
Documents
17
Period of Report
2025-06-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 90095
2 EX-3.1 ex3-1.htm EX-3.1 95883
3 EX-3.2 ex3-2.htm EX-3.2 105344
4 EX-10.1 ex10-1.htm EX-10.1 377861
  Complete submission text file 0001641172-25-017285.txt   1019675

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE bfri-20250627.xsd EX-101.SCH 3975
6 XBRL DEFINITION FILE bfri-20250627_def.xml EX-101.DEF 26989
7 XBRL LABEL FILE bfri-20250627_lab.xml EX-101.LAB 37209
8 XBRL PRESENTATION FILE bfri-20250627_pre.xml EX-101.PRE 25609
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6972
Mailing Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801
Business Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801 781-245-1325
Biofrontera Inc. (Filer) CIK: 0001858685 (see all company filings)

EIN.: 473765675 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40943 | Film No.: 251094276
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)